New York City, NY, USA: This strategic appointment underscores the firm’s dedication to expanding its healthcare investment portfolio.
New York-based healthcare-focused private equity firm, Invidia Capital Management, has welcomed Shaunak Parikh as a Partner. In this capacity, Parikh will oversee the identification of fresh investment prospects and drive growth initiatives across the healthcare sector.
Parikh brings nearly 20 years of experience at the intersection of finance and healthcare, demonstrating expertise across pharmaceuticals, pharmaceutical services, medical devices, diagnostics, and technology-enabled services. He has also served on multiple corporate boards, collaborating with management teams to foster growth and long-term value creation.
“Shaunak has a consistent record of uncovering high-potential opportunities in healthcare products and services,” said Jo Natauri, Founder and Managing Partner of Invidia Capital Management. “His extensive investing background and team-oriented approach will be key as we continue to expand Invidia’s platform.”
Prior to joining Invidia, Parikh held the position of Managing Director at EW Healthcare Partners in New York and previously worked at Health Evolution Partners in San Francisco. He started his professional journey in Citi’s investment banking division, advising on mergers and acquisitions in the medical device and pharmaceutical industries.
“I am thrilled to become part of Invidia at such a transformative stage,” Parikh said. “The firm’s deep healthcare knowledge, operational focus, and commitment to nurturing enduring partnerships with management teams resonate with my investment philosophy. I am eager to collaborate with Jo and the entire team to advance our mission of partnering with world-class companies to create value for patients, providers, and payers.”
Parikh earned an MBA from The Wharton School at the University of Pennsylvania and graduated with Phi Beta Kappa honors from UCLA, where he obtained dual degrees in Microbiology, Immunology & Molecular Genetics and Economics.
